Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 2079-2089

  Degenhardt, Yan ^a   Greshock, Joel ^a   Laquerre, Sylvie ^a   Gilmartin, Aidan G ^a   Jing, Junping ^a   Richter, Mark ^a   Zhang, Xiping ^a   Bleam, Maureen ^a   Halsey, Wendy ^a   Hughes, Ashley ^a   Moy, Christopher ^a   Liu Sullivan, Nancy ^b   Powers, Scott ^b   Bachman, Kurtis ^a   Jackson, Jeffrey ^a,c   Weber, Barbara ^a,d   Wooster, Richard ^a  

^a GLAXOSMITHKLINE   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; GSK 461364A; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; THIOPHENE DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHROMOSOMAL INSTABILITY; DRUG ACTIVITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; TETRAPLOIDY; TREATMENT RESPONSE; WILD TYPE; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; IC50; IMMUNOBLOTTING; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; POLYPLOIDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; MITOSIS; MUTATION; NEOPLASMS; POLYPLOIDY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THIOPHENES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954597123     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0095     Document Type: Article

References (48)

1. Sumara I, Gimenez-Abian JF, Gerlich D, et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004;14:1712-22.
2. van Vugt MA, van de Weerdt BC, Vader G, et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279:36841-54.
3. Lane HA, Nigg EA. Cell-cycle control: POLO-like kinases join the outer circle. Trends Cell Biol 1997;7:63-8.
4. Casenghi M, Meraldi P, Weinhart U, Duncan PI, Korner R, Nigg EA. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev Cell 2003;5:113-25.
5. Dai W, Huang X, Ruan Q. Polo-like kinases in cell cycle checkpoint control. Front Biosci 2003;8:d1128-33.
6. Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005;24:248-59.
7. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-91.
8. Wolf G, Hildenbrand R, Schwar C, et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196:753-9.
9. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148-52.
10. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001;169:41-9.
11. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:2794-7.
12. Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14:543-9.
13. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001;164:41-9. (Pubitemid 32144988)
14. Gray PJ, Jr., Bearss DJ, Han H, et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004;3:641-6.
15. Gilmartin AG, Bleam MR, Richter MC, et al. Distinct concentrationdependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009;69:6969-77.
16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
17. Rusnak DW, Alligood KJ, Mullin RJ, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-94.
18. Spector NL, Xia W, Burris H III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
19. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006;95:1483-9.
20. https://cabig.nci.nih.gov/caArray-GSKdata/.
21. Cann HM, de Toma C, Cazes L, et al. A human genome diversity cell line panel. Science 2002;296:261-2.
22. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-40.
23. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
24. Greshock J, Feng B, Nogueira C, et al. A comparison of DNA copy number profiling platforms. Cancer Res 2007;67:10173-80.
25. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-704.
26. Liu X, Lei M, Erikson RL,. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-108.
27. http://www.sanger.ac.uk/genetics/CGP.
28. http://www-p53.iarc.fr/p53mutfunction.html.
29. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
30. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834-42.
31. Sakuragi N, Watari H, Ebina Y, et al. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 2005;116:514-9.
32. http://www.umd.be:2072/.
33. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2009;17:93-102.
34. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96.
35. Haruki N, Harano T, Masuda A, et al. Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol 2001;159:1345-52.
36. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, TEL-PDGFR fusion proteins. Blood 1997;90:4947-52.
37. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using highthroughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936-41.
38. Nigg EA. Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998;10:776-83.
39. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
40. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-8.
41. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997;57:1013-9.
42. Khan SH, Wahl GM. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 1998;58:396-401.
43. Lanni JS, Jacks T,. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998;18:1055-64. (Pubitemid 28063440)
44. Salvatore G, Nappi TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007;67:10148-58.
45. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009;69:1916-23.
46. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77.
47. Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009;106:3964-9.
48. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.